Project Grant R01HL175474
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$719K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
The University of Nevada, Reno was awarded a $557,649 federal Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the molecular regulation of beta-2 integrin activation in neutrophil adhesion and inflammation. The research aims to decipher the mechanisms by which the proteins Kindlin-3 and Talin-1 induce activation of beta-2 integrins, which play a key role in neutrophil recruitment and inflammation. The study...
This $151,523 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by The Medical College of Wisconsin, Inc. to investigate the role of the protein fibrinogen in regulating inflammatory and clotting processes associated with acute and chronic venous thrombosis (blood clots). The research will utilize novel RNA therapy delivered via lipid nanoparticles to selectively reduce...
This federal Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the innate immune cell profile and cytokine microenvironment that mediate the development of inhibitory antibodies against factor VIII in individuals with hemophilia A. The research aims to 1) examine the cytokine profile and activation of conventional dendritic cells (CDC2) that drive CD4+ T cell...
This $131,250 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant will support a research project led by Vitalant Research Institute (VRI) to investigate the potential for transfusion-transmitted cerebral amyloid angiopathy (CAA). The key objectives are to: (A) assess the prevalence of amyloid-beta pathology among blood donors using the PTAU217 protein marker, and (B)...
This $1,999,247 federal Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the success and failure of allogeneic virus-specific T-cell (VST) therapy for treating viral infections in patients who have undergone hematopoietic stem cell transplantation. The research aims to improve understanding of both patient-specific and virus-specific factors that influence the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $236,833 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel intracellular targeting nanobody that blocks Connexin 43 (Cx43)-mediated pathological proliferation of smooth muscle cells (SMCs). The project aims to design and test these small antibody fragments called nanobodies, which can enter cells, to disrupt the Cx43-Cyclin E...
This $686,458 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a collaborative research effort between multiple institutions, led by Yale University, to develop a quantitative, predictive model of vascular remodeling in health and disease. The key products and services to be delivered through this grant include: Characterizing the roles of vascular endothelial...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate how cardiac fibroblasts regulate angiogenesis (blood vessel formation) following myocardial infarction (heart attack). The $740,037 award, with a period of performance from February 1, 2025 to November 30, 2029, will enable the research team at the University of California, Los Angeles (UCLA) to...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $391,250 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate fibrinogen as a mediator of COVID-19-associated coagulopathy. The project aims to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well as the role of the fibrinogen isoform G-gamma-fibrinogen in altering blood biophysical properties and...